Antengene announces acceptance of ind application in china for the phase ii clinical trial of single-agent selinexor for the treatment of myelofibrosis (mf)

Shanghai and hong kong, july 5, 2021 /prnewswire/ -- antengene corporation limited ("antengene", sehk: 6996.hk), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncology, recently announced that china's national medical products administration (nmpa) has accepted the investigational new drug (ind) application for single agent selinexor, a first-in-class orally available exportin 1 (xpo1) inhibitor, for the treatment of patients with myelofibrosis (mf) in china. mf is a clonal hematologic neoplasm which can emerge either as primary mf, polycythemia vera (pv) or essential thrombocythemia (et)[1].
KPTI Ratings Summary
KPTI Quant Ranking